Herpes simplex virus (HSV) infections of humans were first documented in ancient Greece.
Greek scholars, particularly Hippocrates, used the word" herpes," meaning to creep or crawl …

Although the cytotoxic effects of viruses are usually viewed in terms of pathogenicity, it is
possible to harness this activity for therapeutic purposes. Viral genomes are highly versatile …

We have created a double mutant of the herpes simplex virus (HSV) type 1 (termed G207)
with favourable properties for treating human malignant brain tumours: replication …

It has been 9 years since the beginning of the first clinical trial in which an oncolytic virus
was administered to cancer patients. Since then, oncolytic viruses from five different species …

The occurrence of multiple tumors in an organ heralds a rapidly fatal course. Although
intravascular administration may deliver oncolytic viruses/vectors to each of these tumors, its …

Oncolytic herpes simplex virus-1 (HSV-1) mutants possessing mutations in the ICP34. 5 and
ICP6 genes have proven safe through clinical trials. However, ICP34. 5-null viruses may …

Replication-competent, attenuated herpes simplex virus (HSV) vectors have been
developed for viral oncolytic therapy of primary and metastatic malignant brain tumors …

In the search for novel strategies, oncolytic virotherapy has recently emerged as a viable
approach to specifically kill tumor cells. Unlike conventional gene therapy, it uses replication …

A phase I trial of an engineered poliovirus for the treatment of recurrent glioblastoma (GBM)
has attracted attention due to 8 survivors reaching the 24-month and 5 reaching the 36 …

The very deep knowledge acquired on the genetics and molecular biology of herpes
simplex virus (HSV), has allowed the development of potential replication-competent and …